McKesson Corporation (MCK)
| Market Cap | 93.24B +3.7% |
| Revenue (ttm) | 403.43B +12.4% |
| Net Income | 4.76B +44.5% |
| EPS | 38.38 +49.2% |
| Shares Out | 120.20M |
| PE Ratio | 20.21 |
| Forward PE | 17.52 |
| Dividend | $3.28 (0.42%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 981,990 |
| Open | 764.00 |
| Previous Close | 756.95 |
| Day's Range | 759.85 - 781.27 |
| 52-Week Range | 637.00 - 999.00 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 949.73 (+22.44%) |
| Earnings Date | May 7, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MCK stock is "Strong Buy." The 12-month stock price target is $949.73, which is an increase of 22.44% from the latest price.
News
McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affi...
McKesson Transcript: Bank of America Global Healthcare Conference 2026
Strong fiscal 2026 results exceeded targets, driven by specialty pharmaceuticals and operational efficiency. Biosimilars and GLP-1s are key growth areas, with automation and AI supporting margin expansion. Strategic M&A and MedSurg separation position the business for continued growth.
McKesson expects 2027 profit slightly above estimates on drug distribution strength
McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates on Thursday, as the U.S. drug distributor banks on strength in its oncology and spe...
McKesson Earnings Call Transcript: Q4 2026
Fiscal 2026 saw strong growth with revenues up 12% and adjusted EPS up 18%, driven by specialty and oncology platforms. FY27 guidance projects 12–14% EPS growth, continued capital returns, and progress on the Medical-Surgical Solutions separation.
McKesson Earnings release: Q4 2026
McKesson released its Q4 2026 earnings on May 7, 2026, summarizing the period's financial results.
McKesson Slides: Q4 2026
McKesson has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
McKesson Annual report: Q4 2026
McKesson has published its Q4 2026 annual report on May 7, 2026.
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on J...
Is McKesson Stock Still A High-Conviction Compounder?
McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicate...
McKesson to Sell Stake of Medical-Surgical Unit to Apollo
McKesson said Apollo affiliates agreed to buy a minority ownership interest in its medical-surgical solutions business ahead of the unit's planned spinoff.
McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
McKesson said on Monday it will sell a minority stake in its medical-surgical solutions business to investment firm Apollo Funds for $1.25 billion, as it prepares to spin off the unit through an i...
McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of ...
McKesson ideaShare 2026 Invites Independent Pharmacists to Learn, Connect and Grow
IRVING, Texas--(BUSINESS WIRE)--Registration is now open for McKesson ideaShare 2026, a premier community pharmacy event for independent pharmacy owners and their teams.
McKesson Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership transition is underway with the CFO retiring after reaffirming guidance and overseeing the MedSurg separation. Strong financial results continue, driven by growth in pharmaceutical distribution, Oncology, and technology solutions, with stable trends in generics and specialty. Strategic focus remains on high-growth platforms and disciplined capital allocation.
McKesson Transcript: Leerink Global Healthcare Conference 2026
CFO Britt Vitalone reflected on consistent performance, specialty growth, and technology innovation, including AI and expanded services. Specialty revenues and MSO integrations are strong, while MedSurg prepares for separation. Operational efficiency and customer focus remain priorities.
McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Bria...
McKesson Announces Planned CFO Transition
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful an...
See How Institutional Inflows Make McKesson Fly
McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.
How McKesson Stock Surged 17% In A Day
McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session. The driver for this surge was a strong Q3 earnings report that surpasse...
McKesson boosts 2026 profit forecast amid specialty drug growth
McKesson Corporation raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.
McKesson Earnings Call Transcript: Q3 2026
Delivered record revenue and double-digit adjusted EPS growth, driven by Oncology, Biopharma Services, and North American distribution. Raised full-year EPS guidance, completed European exit, and advanced Medical-Surgical separation, with strong cash flow and continued investment in technology.
McKesson Quarterly report: Q3 2026
McKesson has published its Q3 2026 quarterly earnings report on February 4, 2026.
McKesson Earnings release: Q3 2026
McKesson released its Q3 2026 earnings on February 4, 2026, summarizing the period's financial results.
McKesson Slides: Q3 2026
McKesson has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.